Conference call scheduled for 4:30 p.m. ET todayVK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24In Vivo Data From Novel Amylin Agonist Program Reported at ADA in June; IND in Obesity Planned for 2025SAN DIEGO, July 24, 2024 /PRNewswire/ ...